Peter B. Gilbert
Ph.D., University of Washington, Biostatistics, 1996.
M.S., University of Washington, Biostatistics, 1994.
B.S., University of Washington, Mathematics, 1992.
Clinical trials for HIV vaccines.
Statistical methods in the areas of survival analysis, genetic sequence analysis, surrogate endpoints, causal inference.
For my complete CV including publications go to http://faculty.washington.edu/peterg
American Statistical Association
International Biometrics Society
Honors and Awards
2014, American Statistical Association Fellow
2010, MERIT Award (R37) from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, for the grant, “Statistical Methods in HIV Vaccine Efficacy Trials”
2005-2006, Ross L. Prentice Professorship, University of Washington, Department of Biostatistics
2000-2001, Excellent Teaching Rating, Harvard School of Public Health
1996, Senior Biostatistics Student Award, University of Washington
1995, Outstanding Student Scholarship, University of Washington, School of Public Health and Community Medicine
1994, Honorary Donovan J. Thompson Award, University of Washington, Outstanding Performance as Student in Biostatistics
1992, Phi Beta Kappa, University of Washington
1992, National Honor Society, Golden Key
1992, B.S., Magna Cum Laude, University of Washington
1988-1992, Dean's List, University of Washington
2005-2006, Deputy Director of Statistical Sciences, Fred Hutchinson Cancer Research Center, Statistical Center for HIV/AIDS Research and Prevention (SCHARP)
2004-2008, Research Associate Professor, University of Washington, School of Public Health and Community Medicine, Biostatistics
2002-2004, Research Assistant Professor, University of Washington, School of Public Health and Community Medicine, Department of Biostatistics
2002-2007, Associate Member, Fred Hutchinson Cancer Research Center, Public Health Sciences Division, Biostatistics
2001-2002, Assistant Member, Fred Hutchinson Cancer Research Center
1997, Research Fellow, Harvard University, School of Public Health
1997-2001, Assistant Professor, Harvard University, School of Public Health, Biostatistics
1995-1996, Graduate Research Assistant, University of Washington, HIVNET
Modeling HIV vaccine trials of the future.. Current opinion in HIV and AIDS.. 2016.
Statistical methods for down-selection of treatment regimens based on multiple endpoints, with application to HIV vaccine trials.. Biostatistics (Oxford, England).. 2016.
Power/sample size calculations for assessing correlates of risk in clinical efficacy trials.. Statistics in medicine. 35(21):3745-59.. 2016.
Mark-specific hazard ratio model with missing multivariate marks.. Lifetime data analysis. 22(4):606-25.. 2016.
Joint modeling of longitudinal and survival data with the Cox model and two-phase sampling.. Lifetime data analysis.. 2016.
Analysis of two-phase sampling data with semiparametric additive hazards models.. Lifetime data analysis.. 2016.
Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.. Current opinion in virology. 17:57-65.. 2016.
Search continues for a CMV vaccine for transplant recipients.. The Lancet. Haematology. 3(2):e58-9.. 2016.
Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence.. Journal of acquired immune deficiency syndromes (1999). 73(5):606-608.. 2016.
Preventing HIV-1 Infection in Women using Oral Pre-Exposure Prophylaxis: A Meta-analysis of Current Evidence.. Journal of acquired immune deficiency syndromes (1999).. 2016.
Goodness-of-fit test of the stratified mark-specific proportional hazards model with continuous mark.. Computational statistics & data analysis. 93:348-358.. 2016.
Surrogate Endpoint Evaluation: Principal Stratification Criteria and the Prentice Definition.. Journal of causal inference. 3(2):157-175.. 2015.
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine.. The New England journal of medicine.. 2015.
Immune correlates of vaccine protection against HIV-1 acquisition.. Science translational medicine. 7(310):310rv7.. 2015.
Reply to Dunning.. The Journal of infectious diseases. 212(9):1521-3.. 2015.
Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.. Journal of AIDS & clinical research. 6(5). 2015.
HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition.. Science translational medicine. 7(296):296ra112.. 2015.
Inferences on relative failure rates in stratified mark-specific proportional hazards models with missing marks, with application to HIV vaccine efficacy trials.. Journal of the Royal Statistical Society. Series C, Applied statistics. 64(1):49-73.. 2015.
Use of placebos in Phase 1 preventive HIV vaccine clinical trials.. Vaccine. 33(6):749-52.. 2015.
Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial.. PLoS computational biology. 11(2):e1003973.. 2015.